| Outcome Measures: |
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (Part A), Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment, Baseline to 7 weeks|Number of Participants With One or More Treatment Emergent Adverse Events (Parts B), Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment, Baseline to 6 weeks | Secondary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Part A), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post-dose|Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Parts B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post dose starting on Day 28|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting Day 1|Maximum Observed Drug Concentration (Cmax) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Maximum Observed Drug Concentration (Cmax) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Time to Observed Cmax (Tmax) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Time to Observed Cmax (Tmax) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Elimination Half-Life (T1/2) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Elimination Half-Life (T1/2) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Apparent Clearance of Drug (CL/F) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Apparent Clearance of Drug (CL/F) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Apparent Total Volume of Distribution (VZ/F) (Part A), Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose|Apparent Total Volume of Distribution (VZ/F) (Part B), Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28|Amount of Drug Excreted in Urine (Aet1-t12) (Part A), Data Not Collected for this Parameter, Pre-Dose and 12 hours Post-Dose|Amount of Drug Excreted in Urine (Aet1-t12) (Part B), Data Not Collected for this Parameter, Pre-Dose and 12 hours Post-Dose on Day 28|Amount of Drug Excreted in Urine (Aet0-24) (Part A), Pre-Dose and 24-hours Post-Dose|Amount of Drug Excreted in Urine (Aet0-24) (Part B), Pre-Dose and 24-hours Post-Dose on Day 28|Fraction of Drug Excreted in the Urine (Fe) (Part A), Pre-Dose and 24-hours Post-Dose|Fraction of Drug Excreted in the Urine (Fe) (Part B), Pre-Dose and 24-hours Post-Dose on Day 28|Change From Baseline in Average Plasma Glucose Concentration After Multiple Doses (Part B), Baseline to Day 24-26|Change From Baseline in Postprandial Glucose (Part B), Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28., Day 28|Change From Baseline in C-Peptide Concentration (Part B), Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline-Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28., Day 28|Change From Baseline in Insulin Concentration (Part B), 4.5 hours following Mixed Meal Tolerance Test (MMTT) on Day 28; Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28., Day 28|Fasting Glucose Concentration (Part B), Fasting glucose concentration after 28 day treatment, Baseline to Day 28|Change From Baseline in Weight (Part B), Baseline to Day 28|Change From Baseline in Waist Circumference (Part B), Baseline to Day 28|Change From Baseline in Hip Circumference (Part B), Baseline to Day 28
|
